New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies-Reference-Cited by-同舟云学术

New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies

Published:2011 Issue: Volume:2011 Page:1-11
ISSN:2090-2247
Container-title:Biochemistry Research International
language:en
Short-container-title:Biochemistry Research International

Author:

Devy Laetitia¹,Dransfield Daniel T.²

Affiliation:

1. Merck Serono S.A., 9 Chemin des Mines, Case postale 54, 1211 Geneva 20, Switzerland

2. Cell Biology and Translational Research, Dyax Corp., 300 Technology Square, Cambridge, MA 02139, USA

Abstract

MMP intervention strategies have met with limited clinical success due to severe toxicities. In particular, treatment with broad-spectrum MMP-inhibitors (MMPIs) caused musculoskeletal pain and inflammation. Selectivity may be essential for realizing the clinical potential of MMPIs. Here we review discoveries pinpointing membrane-bound MMPs as mediators of mechanisms underlying cancer and inflammation and as possible therapeutic targets for prevention/treatment of these diseases. We discuss strategies to target these therapeutic proteases using highly selective inhibitory agents (i.e., human blocking antibodies) against individual membrane-bound MMPs.

Publisher

Hindawi Limited

Subject

Biochemistry

Link

http://downloads.hindawi.com/journals/bri/2011/191670.pdf

Reference139 articles.

1. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment

2. Cysteine Array Matrix Metalloproteinase (CA-MMP)/MMP-23 Is a Type II Transmembrane Matrix Metalloproteinase Regulated by a Single Cleavage for Both Secretion and Activation

3. Cloning and Characterization of Human MMP-23, a New Matrix Metalloproteinase Predominantly Expressed in Reproductive Tissues and Lacking Conserved Domains in Other Family Members

4. Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic Evaluation of Protein-Small Molecule Hybrids on the Yeast Surface;ACS Chemical Biology;2024-01-17

2. Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013–2023);Molecules;2023-07-21

3. Inhibition of glioblastoma proliferation, invasion, and migration by Urolithin B through inducing G0 / G1 arrest and targeting MMP ‐2/‐9 expression and activity;BioFactors;2022-10-30

4. Insights Into the Role of Matrix Metalloproteinases in Cancer and its Various Therapeutic Aspects: A Review;Frontiers in Molecular Biosciences;2022-09-29

5. Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology;Pharmacological Reviews;2022-07